Everest Signs a License Agreement with Providence to Advance mRNA Vaccines

 Everest Signs a License Agreement with Providence to Advance mRNA Vaccines

Everest Signs a License Agreement with Providence to Advance mRNA Vaccines

Shots:

  • Providence to receive $100M up front for Providence’s PTX-COVID19-B, mRNA technology & other products, ~$300M upon achievement of milestones, $100M in profit-sharing along with royalties in Greater China & Singapore. Providence is also eligible to receive royalties based on vaccine sales in Everest Territories
  • Everest gains rights to Providence’s PTX-COVID19-B in Greater China, Asia, Pakistan & other countries. PTX-COVID19-B is currently in P-II trials while interim data from the P-I study showed that the vaccine is safe & well tolerated
  • The companies also enter into a 50/50 global collaboration to develop 2 additional prophylactic or therapeutic products by using Providence’s mRNA Platform

Click here to read full press release/ article | Ref: PR Newswire | Image: Crunchbase

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post